{"entity":{"id":"mermaid-1","kind":"trial","name":"MERMAID-1","aka":[],"tldr":"A lung cancer trial that planned to test whether adding the immunotherapy durvalumab to chemotherapy after surgery helps people whose blood shows leftover tumour DNA; the registry lists it as complete with 89 participants.","summary":"MERMAID-1 was AstraZeneca's phase 3, double-blind trial of adjuvant durvalumab with platinum chemotherapy in completely resected stage II to III non-small-cell lung cancer, designed around ctDNA-detected minimal residual disease. The registry records a start on 17 July 2020, a status of completed and 89 participants, with primary and study completion on 31 August 2023. Together with MERMAID-2 it is the main example that a ctDNA-selected escalation trial can be hard to run in lung cancer, where adjuvant immunotherapy was approved for all-comers while the trials were recruiting.","status":"completed","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT04385368","url":"https://clinicaltrials.gov/study/NCT04385368"}],"tags":["ctdna-roadmap"],"related":["mermaid-2","ctdna-tests"],"cancers":["nsclc"],"sections":[],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":["durvalumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":["mrd","ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04385368","phase":"3","setting":"Completely resected stage II to III non-small-cell lung cancer: adjuvant durvalumab plus platinum chemotherapy against placebo plus chemotherapy, with ctDNA-positive patients as the group of interest","sponsor":"AstraZeneca","enrolled":89,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/mermaid-1/","neighbours":{"trial":[{"id":"mermaid-2","kind":"trial","name":"MERMAID-2","route":"/trials/mermaid-2/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}]}}